NEW YORK, May 22 - Tranzyme and Targacept said today they will team to develop a bioassay that might help discover drugs for central nervous system disorders.
The deal, which the firms say also includes a licensing component, calls for Tranzyme to use its TranzVector gene-transfer technology and TranzAssay assay-development tool to create a cell-based assay to express a CNS-based receptor provided by Targacept.
Targacept will enrich Tranzyme with developmental support and royalties on sales of any products screened by Targacept with the assay. Tranzyme also will retain the rights to develop the bioassay for its own neurosensory drug discovery.
Click here for more information.